Freudenberg Medical Completes Extractables Testing for Biopharma Tubing
The company worked with Eurofins Lancaster Laboratories to conduct independent extractables testing that involved eight solvents tested over a 21-day exposure time frame.
Freudenberg Medical, a contract manufacturer of medical device components and pharmaceutical tubing, announced it has completed testing on its PharmaFocus Premium silicone tubing used in biopharma fluid processing and single-use applications.
The company worked with Eurofins Lancaster Laboratories to conduct independent extractables testing that involved eight solvents tested over a 21-day exposure time frame, a May 18, 2020 company press release said. The tubing also underwent added physical, chemical, and biological tests.
“We understand that identifying extractable and leachable substances is extremely important for our biopharma customers,” said Jeff Mohror, vice-president and general manager of Freudenberg Medical Carpinteria, in the press release. “When specifying tubing into a process, this data will save customers valuable time and cost when bringing a new process into production.”
Source: Freudenberg Medical
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
